Gain firsthand insight into how judges from the PTAB and federal courts in key jurisdictions are approaching pharmaceutical and biotech patent disputes. This session offers a rare opportunity to hear directly from the decision-makers on litigation strategy, evidentiary expectations, and what most influences outcomes in complex patent cases.
Klaus Grabinski
Roy Payne
Kent Jordan
Kent A. Jordan is a Director in the Wilmington, Delaware law firm of Richards, Layton & Finger. Previously, since 2006, he served as a United States Circuit Judge for the Third Circuit. Before that, he was a United States District Judge for the District of Delaware from 2002 to 2006. Judge Jordan received a B.A. in Economics in 1981 from Brigham Young University and a J.D. in 1984 from Georgetown University. He was an Assistant United States Attorney and head of the Civil Division in the U.S. Attorney’s Office for the District of Delaware. Later, he served as an officer and as a member of the boards of directors of privately held businesses and was a partner in a law firm. He is an Adjunct Professor of Law at the University of Pennsylvania and Vanderbilt University and has served as President of the Board of Trustees of the American Inns of Court Foundation, as well as on the boards of other non-profit organizations.
Christopher J. Burke
Brian P. Murray
Brian counsels clients across the biotechnology, pharmaceutical, chemical, and engineering industries on complex intellectual property and technology disputes. He represents companies in high-stakes patent litigation involving biotechnology and biosynthesis, pharmaceuticals, plastics, telecommunications, and LED technologies, helping clients align legal strategies with scientific, regulatory, and business objectives.
Drawing on his background in pharmaceutical research and development, Brian represents clients in Hatch-Waxman litigation and has helped guide multiple matters through trial. He also advises those pharmaceutical clients on pre-suit strategy, product selection, portfolio management, formulation development, labeling considerations, and regulatory matters.
A significant portion of Brian’s practice focuses on biotechnology innovators, particularly those developing bioengineering and fermentation technologies. He has extensive experience litigating patents related to metabolic engineering and microbial strain development and is skilled at translating highly technical concepts into clear, compelling litigation and counseling strategies.
Before attending law school, Brian worked as a formulation development scientist at Caraco Pharmaceutical Laboratories and gained experience in pharmaceutical synthesis at Fabbrica Italiana Sintetici S.p.A., providing him with a practical understanding of the industries he serves.